How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician criterion.  However, leaving the decision to one single specialist might not be the best. This is when the team’s role becomes essential. 

Cómo suspender la antiagregación previa a una cirugía no cardíaca

This study looked at the advantages consensus decision-making amongst clinicians, surgeons and anesthesiologists to continue or not antiplatelet therapy in patients with second generation drug eluting stents (DES) prior a non-cardiac surgery. 

3582 patients with prior DES stenting receiving non-cardiac surgery were retrospectively included. 3103 patients consulted with the team and follow their recommendation. 

Patients on arbitrarily managed dual antiplatelet therapy (DAPT) before or during surgery presented higher risk of bleeding during surgery and more emergency surgery. These patients were more frequently women and were on DAPT at consultation. 

Arbitrary DAPT decision making nearly doubled the risk of net clinical adverse events  (OR 1.98, CI 95%, 1.98–3.11), tripled cardiovascular events (OR 3.11; CI 95%, 1.31–7.34) and doubled major bleeding (OR 2.34; CI 95%, 1.45–3.76).


Read also: Watch again our Webinar “SOLACI@BIOTRONIK” on our Youtube account.


This association was consistent irrespective of non-cardiac surgery, risk or recommendation on DAPT management. 

Conclusion

DAPT management prior non-cardiac surgery should be decided on a case-by-case basis, and all involved in the procedure should have a say (cardiologist, surgeon, anesthesiologist, etc.). 

The risk of major adverse events have a two and three-fold increase when DAPT management is arbitrary and individually made by a single team member. 

JAHA.120.020079free

Original title: Consensus Decision-Making for the Management of Antiplatelet Therapy before Non-Cardiac Surgery in Patients Who Underwent Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents: A Cohort Study.

Reference: Choongki Kim et al. J Am Heart Assoc. 2021 Apr 20;10(8):e020079. doi: 10.1161/JAHA.120.020079.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Left or Right Transradial Approach? Comparing Radiation Exposure in Coronary Procedures

Radiation exposure during percutaneous procedures is a problem both for patients and operators. The transradial is currently the preferred approach, vs. femoral; however, whether...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....